Google joins with HCA and SADA to take on COVID-19

HCA Healthcare, the 185-hospital, publicly traded provider company based in Nashville, is partnering with Google Cloud and the tech-services supplier SADA to offer communities an open-access data platform.

The trio’s aim is to help local healthcare providers coordinate their response to COVID-19.

Called the COVID-19 National Response Portal, the platform is designed to help healthcare providers quickly find out where their locality stands on things like ventilator utilization, testing results ICU bed availability and COVID patient discharges.

According to an HCA news release, hospital systems across the U.S. can contribute to the national pandemic response by submitting data to the portal each day.

“As healthcare providers, we are all battling the same crisis,” says Michael Wargo, HCA’s vice president of emergency preparedness. “However, we are being faced with COVID-19 at different times and levels of severity. By pooling our data into one cohesive platform, we can share best practices to better prepare communities across the country for this unprecedented pandemic.”

The portal was built by SADA and is running on Google Cloud.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.